Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy
更正:根据一项通过组织和液体活检进行的临床多中心研究,携带 TP53 R273C 或 KRAS G12V 突变的 EGFR T790M 晚期 NSCLC 患者无法从奥希替尼治疗中获益。
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2023.1236311
Fu, Yulong; Wang, Anqi; Zhou, Jieqi; Feng, Wei; Shi, Minhua; Xu, Xiao; Zhao, Hongqing; Cai, Liming; Feng, Jian; Lv, Xuedong; Zhang, Xiaodong; Xu, Wenjing; Zhang, Zhengrong; Ma, Guoer; Wang, Jian; Zhou, Tong; Zhao, Dahai; Fang, Haohui; Liu, Zeyi; Huang, Jian-An